Determinants of Paucibacillary Mtb Infection in Mice
- Institution
- WEILL MEDICAL COLL OF CORNELL UNIV, NY
- Principal investigator
- Sabine Ehrt
- Funding
- $338K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
Tuberculosis (TB) chemotherapy eliminates disease symptoms, but often fails to sterilize Mycobacterium tuberculosis (Mtb) leaving apparently cured TB patients at risk of disease relapse. How Mtb survives during post- treatment persistent infections (PTPI) is ill defined and we lack a full understanding of the immune determinants that prevent progression to active TB (relapse). We developed a paucibacillary (low bacterial numbers) mouse model that mimics PTPI in in humans. We found that silencing of in vivo essential genes cured Mtb infections in mice to the extent that colony forming units (CFU) were no longer detected on agar plates. However, as in humans, mice were often not sterilized, and paucibacillary infection resulted in relapse TB. Our model allows us to interrogate both, the mechanisms that enable Mtb to persist despite host immunity and the host factors that are required to control and sterilize Mtb infection. We will use this model to (1) compare post-treatment persistent infection (PTPI) in mice and humans (2) determine the importance of specific leukocyte subsets for the establishment or control of paucibacillary Mtb infection and (3) identify Mtb genes that are required for paucibacillary persistence.
LOADING MOONBASE SCORE
Questions for WEILL MEDICAL COLL OF CORNELL UNIV
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Weill Medical Coll of Cornell UnivNot yet scored
Determinants of TB control, relapse and reinfection
Sabine Ehrt · $203K · 2025–2026
- NIH · Weill Medical Coll of Cornell UnivNot yet scored
M. tuberculosis carbon metabolism during infection
Sabine Ehrt · $817K · 2023–2028
- NIH · Weill Medical Coll of Cornell UnivNot yet scored
Determinants of TB control, relapse and reinfection
Sabine Ehrt · $2.3M · 2021–2026